查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1521258

2024-2032 年按疾病类型（活动性结核病、潜伏性结核病等）、诊断和治疗（诊断、治疗）、最终用户（医院、专科诊所、家庭护理等）和地区分類的抗结核治疗市场报告

Anti-Tuberculosis Therapeutics Market Report by Disease Type (Active TB, Latent TB, and Others), Diagnosis and Treatment (Diagnosis, Treatment), End User (Hospitals, Specialty Clinics, Homecare, and Others), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年，全球抗结核治疗市场规模达14.456亿美元。不断增长的医疗保健支出、有利的报销政策、技术进步以及不断增长的公私合作伙伴关係是推动市场发展的一些关键因素。

抗结核治疗是指用于控制结核病（TB）的药物和治疗策略，结核病是由结核分枝桿菌引起的细菌感染。结核病主要影响肺部，也可以扩散到身体的其他部位，例如肾臟、脊椎和大脑。抗结核治疗用于消灭体内的细菌并防止感染传播。这是透过合併使用抗生素来实现的，通常开出六到九个月的处方。一些最常用的药物包括异烟肼、利福平、乙胺丁醇和吡嗪酰胺。所使用的药物的确切组合取决于感染的严重程度和患者的健康状况。此外，定期监测和追踪对于确保治疗成功和预防抗药性结核病的发展也至关重要。近年来，抗结核治疗受到关注，因为它还涉及支持性护理，例如氧气治疗、营养支持和可能出现的併发症的管理。

抗结核治疗市场趋势：

推动市场的主要因素之一是全球结核病（TB）的高盛行率，特别是在低收入和中等收入国家。此外，由于治疗不完整、医疗基础设施不足以及缺乏适当的医疗保健，抗药性结核病的发生率不断上升，这对市场成长产生了积极影响。除此之外，新药和治疗策略的发展也正在推动抗结核治疗市场。近年来，贝达喹啉和德拉马尼等多种新药已被批准用于治疗结核病。与传统结核病药物相比，这些药物的疗效和安全性更高。与此一致的是，技术和诊断的进步使得结核病的早期检测和诊断成为可能，从而及时开始治疗并改善患者的预后，这是另一个主要的生长诱导因素。此外，医疗保健支出的增加，特别是在新兴经济体，改善了医疗保健基础设施，并增加了获得优质医疗保健（包括结核病治疗）的机会。除此之外，人们对结核病的认识不断提高以及早期诊断和治疗的重要性也增加了抗结核治疗的需求。此外，政府对结核病控制计画的措施和资助在推动抗结核治疗市场方面发挥了重要作用。例如，政府和非政府组织 (NGO) 正在共同努力提高意识、改进诊断并确保获得负担得起且有效的治疗，预计这将在未来几年推动市场成长。

本报告回答的关键问题：

  • 迄今为止，全球抗结核治疗市场表现如何，未来几年将如何表现？
  • 全球抗结核治疗市场的驱动因素、限制因素和机会是什么？
  • 每个驱动因素、限制因素和机会对全球抗结核治疗市场有何影响？
  • 主要区域市场有哪些？
  • 哪些国家代表了最具吸引力的抗结核治疗市场？
  • 根据疾病类型的市场划分是怎样的？
  • 抗结核治疗市场上最具吸引力的疾病类型是什么？
  • 基于诊断和治疗的市场区隔是什么？
  • 抗结核治疗市场上最具吸引力的诊断和治疗方法是什么？
  • 基于最终用户的市场区隔是什么？
  • 抗结核治疗市场中哪一个是最具吸引力的最终用户？
  • 全球抗结核治疗市场的竞争结构如何？
  • 全球抗结核治疗市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球抗结核治疗市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依疾病类型

  • 活动性结核病
    • 市场走向
    • 市场预测
  • 潜伏性结核病
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：市场区隔：透过诊断与治疗

  • 诊断
    • 市场走向
    • 关键环节
      • 血液检查
      • 影像学检查
      • 痰液测试
      • 其他的
    • 市场预测
  • 治疗
    • 市场走向
    • 关键环节
      • 一线药物
        • 主要类型
        • 异烟肼
        • 乙胺丁醇
        • 利福平
        • 其他的
      • 二线药物
        • 主要类型
        • 硫醋腙
        • 对氨基水杨酸 (PAS)
        • 其他的
      • 其他的
    • 市场预测

第 8 章：市场区隔：依最终用户

  • 医院
    • 市场走向
    • 市场预测
  • 专科诊所
    • 市场走向
    • 市场预测
  • 居家护理
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：驱动因素、限制与机会

  • 概述
  • 司机
  • 限制
  • 机会

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • F. Hoffmann-La Roche Ltd.
    • Lannett Company Inc.
    • Lupin Limited
    • Macleods Pharmaceuticals Limited
    • Otsuka Pharmaceutical Co. Ltd
Product Code: SR112024A7629

The global anti-tuberculosis therapeutics market size reached US$ 1,445.6 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 2,448.5 Million by 2032, exhibiting a growth rate (CAGR) of 5.85% during 2024-2032. The rising healthcare spending, favorable reimbursement policies, technological advancements, and growing public-private partnerships represent some of the key factors driving the market.

Anti-tuberculosis therapeutics refer to the drugs and treatment strategies used to manage tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis. TB primarily affects the lungs and can also spread to other parts of the body, such as the kidneys, spine, and brain. Anti-tuberculosis therapeutics are used to eradicate the bacteria from the body and prevent the spread of the infection. This is achieved through a combination of antibiotics that are typically prescribed for six to nine months. Some of the most commonly used drugs include isoniazid, rifampin, ethambutol, and pyrazinamide. The exact combination of drugs used depends on the severity of the infection and the patient's health status. In addition, regular monitoring and follow-up are also essential to ensure treatment success and prevent the development of drug-resistant TB. In recent years, anti-tuberculosis therapeutics have gained traction as it also involves supportive care, such as oxygen therapy, nutrition support, and management of complications that may arise.

Anti-Tuberculosis Therapeutics Market Trends:

One of the primary factors driving the market is the high prevalence of tuberculosis (TB) worldwide, particularly in low- and middle-income countries. Additionally, the growing incidence of drug-resistant TB due to incomplete treatment, inadequate healthcare infrastructure, and lack of access to appropriate healthcare is positively influencing the market growth. Other than this, the development of new drugs and treatment strategies is also driving the anti-tuberculosis therapeutics market. In recent years, several new drugs, such as bedaquiline and delamanid, have been approved for the treatment of TB. These drugs offer improved efficacy and safety profiles compared to traditional TB drugs. In line with this, advancements in technology and diagnostics have enabled early detection and diagnosis of TB, leading to timely initiation of treatment and better patient outcomes, which represents another major growth-inducing factor. Furthermore, the increase in healthcare spending, particularly in emerging economies, has led to improved healthcare infrastructure and increased access to quality healthcare, including TB treatment. Apart from this, the growing awareness about TB and the importance of early diagnosis and treatment has also escalated the demand for anti-tuberculosis therapeutics. Moreover, government initiatives and funding for TB control programs have played a significant role in driving the anti-tuberculosis therapeutics market. For instance, governments and non-governmental organizations (NGOs) are working together to increase awareness, improve diagnosis, and ensure access to affordable and effective treatments, which is expected to drive market growth in the upcoming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global anti-tuberculosis therapeutics market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on the disease type, diagnosis and treatment, and end user.

Disease Type Insights:

Active TB

Latent TB

Others

The report has provided a detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the disease type. This includes active TB, latent TB, and others.

Diagnosis and Treatment Insights:

Diagnosis

Blood Tests

Imaging Tests

Sputum Tests

Others

Treatment

First-Line of Drugs

Isoniazid

Ethambutol

Rifampin

Others

Second-Line of Drugs

Thiacetazone

Paraaminosalicyclic Acid (PAS)

Others

Others

A detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the diagnosis and treatment has also been provided in the report. This includes diagnosis (blood tests, imaging tests, sputum tests, and others), treatment (first-line of drugs (isoniazid, ethambutol, rifampin, and others) second-line of drugs (thiacetazone, paraaminosalicyclic acid (PAS), and others), and others

End User Insights:

Hospitals

Specialty Clinics

Homecare

Others

The report has provided a detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the end user. This includes hospitals, specialty clinics, homecare, and others.

Regional Insights:

North America

United States

Canada

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for anti-tuberculosis therapeutics. Some of the factors driving the North America anti-tuberculosis therapeutics market included rising prevalence of tuberculosis, growing drug resistance, and numerous government initiatives.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global anti-tuberculosis therapeutics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include F Hoffmann-La Roche Ltd., Lannett Company Inc., Lupin Limited, Macleods Pharmaceuticals Limited, Otsuka Pharmaceutical Co. Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global anti-tuberculosis therapeutics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global anti-tuberculosis therapeutics market?
  • What is the impact of each driver, restraint, and opportunity on the global anti-tuberculosis therapeutics market?
  • What are the key regional markets?
  • Which countries represent the most attractive anti-tuberculosis therapeutics market?
  • What is the breakup of the market based on the disease type?
  • Which is the most attractive disease type in the anti-tuberculosis therapeutics market?
  • What is the breakup of the market based on the diagnosis and treatment?
  • Which is the most attractive diagnosis and treatment in the anti-tuberculosis therapeutics market?
  • What is the breakup of the market based on end user?
  • Which is the most attractive end user in the anti-tuberculosis therapeutics market?
  • What is the competitive structure of the global anti-tuberculosis therapeutics market?
  • Who are the key players/companies in the global anti-tuberculosis therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Anti-Tuberculosis Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Disease Type

  • 6.1 Active TB
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Latent TB
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Diagnosis and Treatment

  • 7.1 Diagnosis
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Blood Tests
      • 7.1.2.2 Imaging Tests
      • 7.1.2.3 Sputum Tests
      • 7.1.2.4 Others
    • 7.1.3 Market Forecast
  • 7.2 Treatment
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 First-Line of Drugs
        • 7.2.2.1.1 Major Types
        • 7.2.2.1.1.1 Isoniazid
        • 7.2.2.1.1.2 Ethambutol
        • 7.2.2.1.1.3 Rifampin
        • 7.2.2.1.1.4 Others
      • 7.2.2.2 Second-Line of Drugs
        • 7.2.2.2.1 Major Types
        • 7.2.2.2.1.1 Thiacetazone
        • 7.2.2.2.1.2 Paraaminosalicyclic Acid (PAS)
        • 7.2.2.2.1.3 Others
      • 7.2.2.3 Others
    • 7.2.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Specialty Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Homecare
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 F. Hoffmann-La Roche Ltd.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 SWOT Analysis
    • 14.3.2 Lannett Company Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Lupin Limited
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Macleods Pharmaceuticals Limited
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Otsuka Pharmaceutical Co. Ltd
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Anti-Tuberculosis Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Disease Type (in %), 2023
  • Figure 5: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Diagnosis and Treatment (in %), 2023
  • Figure 6: Global: Anti-Tuberculosis Therapeutics Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Anti-Tuberculosis Therapeutics (Active TB) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Anti-Tuberculosis Therapeutics (Active TB) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Anti-Tuberculosis Therapeutics (Latent TB) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Anti-Tuberculosis Therapeutics (Latent TB) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Anti-Tuberculosis Therapeutics (Other Disease Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Anti-Tuberculosis Therapeutics (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Anti-Tuberculosis Therapeutics (Diagnosis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Anti-Tuberculosis Therapeutics (Diagnosis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Anti-Tuberculosis Therapeutics (Treatment) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Anti-Tuberculosis Therapeutics (Treatment) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Anti-Tuberculosis Therapeutics (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Anti-Tuberculosis Therapeutics (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Anti-Tuberculosis Therapeutics (Specialty Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Anti-Tuberculosis Therapeutics (Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Anti-Tuberculosis Therapeutics (Homecare) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Anti-Tuberculosis Therapeutics (Homecare) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Anti-Tuberculosis Therapeutics (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Anti-Tuberculosis Therapeutics (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: North America: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: North America: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: United States: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: United States: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Canada: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Canada: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Asia-Pacific: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Asia-Pacific: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: China: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: China: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Japan: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Japan: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: India: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: India: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: South Korea: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: South Korea: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Australia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Australia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Indonesia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Indonesia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Europe: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Europe: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Germany: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Germany: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: France: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: France: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: United Kingdom: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: United Kingdom: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Italy: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Italy: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Spain: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Spain: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Russia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Russia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Latin America: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Latin America: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Brazil: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Brazil: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Mexico: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Mexico: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Middle East and Africa: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Middle East and Africa: Anti-Tuberculosis Therapeutics Market: Breakup by Country (in %), 2023
  • Figure 74: Middle East and Africa: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Global: Anti-Tuberculosis Therapeutics Industry: Drivers, Restraints, and Opportunities
  • Figure 76: Global: Anti-Tuberculosis Therapeutics Industry: Value Chain Analysis
  • Figure 77: Global: Anti-Tuberculosis Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Anti-Tuberculosis Therapeutics Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Disease Type (in Million US$), 2024-2032
  • Table 3: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Diagnosis and Treatment (in Million US$), 2024-2032
  • Table 4: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Anti-Tuberculosis Therapeutics Market: Competitive Structure
  • Table 7: Global: Anti-Tuberculosis Therapeutics Market: Key Players